[1] Bonds, D.R. (2003) Three Decades of Innovation in the Management of Sickle Cell Disease: The Road to Understanding the Sickle Cell Disease Phenotype. Blood Reviews, 19, 99-110.
http://dx.doi.org/10.1016/j.blre.2004.04.002
[2] Dampier, C. and Setty, B.N.Y. (2004) Vaso-Constriction in Children with Sickle Cell Disease: Clinical Characteristics and Biologic Correlations. Journal of Pediatric Hematology/Oncology, 29, 785-790.
[3] Benjamin, L.J. (2001) The Nature and Management of Acute Pain Episode in Sickle Cell Disease. In: Forget, B.G., Higgs, D., Nagel, R.L. and Steinberg, M.H., Eds., Diseases of Hemoglobin, Cambridge University Press, Cambridge, 671-710.
[4] de Franceschi, L., Finco, G., Vassanelli, A., Zaia, B., Ischia, S. and Corrocher, R. (2004) A Pilot Study on the Efficacy of Ketorolac plus Tramadol Infusion Combined with Erythrocytapheresis in the Management of Acute Severe Vaso-Occlusive Crises and Sickle Cell Pain. Haematologica, 489, 1389-1391.
[5] Krisnamoorthy, P., Alyaarubi, S., Abish, A., Gale, M., Abuquerque, P. and Jabado, N. (2006) Primary Hyperparathyroidism Mimicking Vaso-Occlusive Crises in Sickle Cell Disease. Journal of Pediatrics, 118, e537-e539.
http://dx.doi.org/10.1542/peds.2006-0337
[6] Aliyu, Z.K., Tumblin, A.R. and Kato, G.J. (2006) Current Therapy of Sickle Cell Disease. Haematologica, 91, 7-10.
[7] Jison, M.L., Munson, P.J., Barb, J.F., Suffredini, A.F., Talwar, S., Logun, C., Raghavachori, N., Beigel, J.H., Danner, R.L. and Gladwin, M.T. (2004) Blood Mononuclear Cell Gene Expression Profiles Characterize the Oxidant, Hemolytic, and Inflammatory Stress in the Expression of Sickle Cell Disease. Blood, 104, 270-280.
http://dx.doi.org/10.1182/blood-2003-08-2760
[8] Hankins, J. and Aygun, B. (2009) Pharmacotherapy in Sickle Cell Disease—State of the Art and Future Prospects. British Journal of Haematology, 145, 296-308.
http://dx.doi.org/10.1111/j.1365-2141.2009.07602.x
[9] Payan, D.G. and Katzung, B.G. (1992) Nonsteroidal Anti-Inflammatory Drugs: Nonopioid Analgesics; Drugs Used in Gout. In: Katzung, B.G., Ed., Basic and Clinical Pharmacology, 6th Edition, Appleton and Lange, Norwalk, Connecticut, 535-557.
[10] Gringauz, A. (1997) Introduction to Medicinal Chemistry. Wiley-VCH, New York, 144,205,235,251,265-266.
[11] Lindenbaum, J. and Klipstein, F.A. (1963) Folic Acid Deficiency in Sickle Cell Disease. New England Journal of Medicine, 269, 875-882.
http://dx.doi.org/10.1056/NEJM196310242691701
[12] Lindenbaum, J. (1997) Workshop on Human Folate Requirements Folic Acid Biochemistry and Physiology in Relation to Human Nutritional Requirement. National Academy of Sciences, Washington DC, 256-276.
[13] Yardurmian, A. and Crawley, C. (2001) Sickle Cell Disease. Clinical Medicine, 1, 441-451.
http://dx.doi.org/10.7861/clinmedicine.1-6-441
[14] Sadarangani, M., Makani, J., Komba, A.N., Ajala-Agbo, T., Newton, C.R., Marsh, K. and Williams, T.N. (2009) An Observational Study of Children in Kilifi, Kenya. British Journal of Haematology, 146, 675-682.
http://dx.doi.org/10.1111/j.1365-2141.2009.07771.x
[15] Prasad, A.S. (1993) Clinical Spectrum of Human Zinc Deficiency. In: Prasad, A.S., Ed., Biochemistry of Zinc, Plenum, New York, 219-258.
http://dx.doi.org/10.1007/978-1-4757-9444-1_11
[16] Prasad, A.S. (1997) [Editorial] Malnutrition in Sickle Cell Disease Patients. American Journal of Clinical Nutrition, 66, 423-424.
[17] Lambright-Eckker, J.A. and Stimmel-Fair, J.M. (1996) Pharmacology Essentials. WB Saunders Company, Philadelphia, 179,207.
[18] World Health Organisation (2003) The Africa Malaria Report.
http://www.afro.who.int
[19] Konotey-Ahulu, F.I.D (1991) The Sickle Disease Patient. Macmillan, London.